Biodistribution and Kinetics of 191Pt in Patients Undergoing Therapy with Cisplatin

Areberg, Johan; Norrgren, Kristina; Björkman, Sven; Einarsson, L.; Lundkvist, H.; Mattsson, Sören; Nordberg, B.; Scheike, Ole; Wallin, Ronnie

doi:10.1007/978-3-0348-7772-5_53

Cited by 7 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), respectively). In general, the pharmacokinetics of the complex shows some similarity to that observed for cisplatin and other platinum-based drugs [19,20,22,23,27,28]. However, it should be noted that concentrations of the currently studied radioactive Pt(IV) complex in the liver and spleen were approximately two times higher comparing to that observed for Pt(II)Cl 2 [ 131 I]Hist complex [27].…”

Section: Biodistribution Of Pt(iv)([ 131 I]histamine)mentioning

confidence: 92%

“…Several radioactive analogues of cisplatin, carboplatin and iproplatin, etc., have been synthesised using platinum radionuclides such as: 195m Pt (4.02 d; IT, e À ), 193m Pt (4.33 d; IT, e À ) and 191 Pt (2.9 d; EC, cÞ. Their utilities for determination of pharmacokinetics of platinum-cytostatics, and therapeutic efficacy of internal radio-chemotherapy have been extensively studied [15,[19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis and preliminary evaluation of the new water-soluble radioactive platinum(IV) complexes

Garnuszek

Maurin

Skierski

et al. 2004

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

Section: Biodistribution Of Pt(iv)([ 131 I]histamine)mentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Synthesis and preliminary evaluation of the new water-soluble radioactive platinum(IV) complexes

Garnuszek

Maurin

Skierski

et al. 2004

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

“…Leeuwenburgh and co-workers utilized [ 195m Pt] labeling strategy to study bone targetability of a bisphosphonate-functionalized Pt anticancer drug using micro-SPECT/CT imaging in mice [ 134 ]. In a few earlier studies, 191 Pt was also used to radiolabel Pt drugs for studying biodistribution and kinetics in patients undergoing cisplatin treatment [ 135 , 136 ]. However, its high energy γ photons (539 keV) are not ideal for high contrast radioimaging using modern γ-camera [ 132 , 133 ].…”

Section: Theranostics Comprising Radioimagingmentioning

confidence: 99%

Challenges and opportunities in the development of metal-based anticancer theranostic agents

2022

View full text Add to dashboard Cite

Around 10 million fatalities were recorded worldwide in 2020 due to cancer and statistical projections estimate the number to increase by 60 % in 2040. With such a substantial rise in the global cancer burden, the disease will continue to impose a huge socio-economic burden on society. Currently, the most widely used clinical treatment modality is cytotoxic chemotherapy using platinum drugs which is used to treat variety of cancers. Despite its clinical success, critical challenges like resistance, off-target side effects and cancer variability often reduce its overall therapeutic efficiency. These challenges require faster diagnosis, simultaneous therapy and a more personalized approach towards cancer management. To this end, small-molecule ‘theranostic’ agents have presented a viable solution combining diagnosis and therapy into a single platform. In this review we present a summary of recent efforts in the design and optimization of metal-based small-molecule ‘theranostic’ anticancer agents. Importantly, we highlight the advantages of a theranostic candidate over the purely therapeutic or diagnostic agent in terms of evaluation of their biological properties.

show abstract

“…114 Similar works, performed by NAA, point out liver, kidney and testicles as the organs that accumulate cisplatin the most. 30 The gamma camera spectroscopy employed by Areberg et al 115 is an interesting contribution to visualise the cisplatin accumulation and distribution. Recent studies carried out by ICP-MS agree with the preferential Pt accumulation in kidney and liver from rats treated with cisplatin, carboplatin and oxaliplatin.…”

Section: Accumulation and Distribution In Tissues Of Pt-based Drugsmentioning

confidence: 99%

Analytical methodologies for metallomics studies of antitumor Pt-containing drugs

et al. 2010

View full text Add to dashboard Cite

Pt-containing drugs are nowadays essential components in cancer chemotherapy. However, drug resistance and side effects limit the efficiency of the treatments. In order to improve the response to Pt-based drugs, different administration strategies or new Pt-compounds have been developed with little success. The reason for this failure could be that the mechanism of action of these drugs is not completely understood. In this way, metallomics studies may contribute to clarify the interactions of Pt-containing drugs within the organism. This review is mainly focused on the role of Analytical Chemistry on the study of the interactions between Pt-based drugs and biomolecules. A summary of the analytical techniques and the most common sample treatment procedures currently used in metallomics studies of these drugs is presented. Both are of paramount importance to study these complex samples preserving the drug-biomolecule interaction. Separation and detection techniques must be carefully selected in order to achieve the intended goals. The use of multidimensional hyphenated techniques is usually necessary for a better understanding of the Pt-based drugs interactions in the organism. An overview of Pt-drugs biological interactions is presented, considering the different sample matrices and the drugs course through the organism. Samples analysed in the included studies are blood, urine, cell cytosol, DNA as well as the drugs themselves and their derivatives. However, most of these works are based on in vitro experiments or incubations of standards, leading in some cases to contradictory results depending on the experimental conditions used. Though in vivo experiments represent a great challenge due to the high complexity and the low concentrations of the Pt-adducts in real samples, these studies must be undertaken to get a deeper understanding of the real interactions concerning Pt-containing drugs.

show abstract

Biodistribution and Kinetics of 191Pt in Patients Undergoing Therapy with Cisplatin

Cited by 7 publications

References 2 publications

Synthesis and preliminary evaluation of the new water-soluble radioactive platinum(IV) complexes

Synthesis and preliminary evaluation of the new water-soluble radioactive platinum(IV) complexes

Challenges and opportunities in the development of metal-based anticancer theranostic agents

Analytical methodologies for metallomics studies of antitumor Pt-containing drugs

Contact Info

Product

Resources

About